Document:

Exhibit 10.13

 

EPIEN Medical, Inc.

 

KEY EMPLOYEE/EXECUTIVE
SEVERANCE AND CHANGE OF CONTROL PLAN

Effective Date: June
1, 2022

 

1. Purpose.
The purpose of the EPIEN Medical, Inc. Executive Severance and Change of Control Plan (the “Plan”) is to provide reasonable
severance protection to certain executive officers and other key employees of the Company and its Affiliates who are expected to make
substantial contributions to the success of the Company and thereby provide for stability and continuity of management.

 

2. Term. The
Plan shall commence upon the Effective Date (as defined below) and shall continue until terminated in accordance with Section 19.

 

3. Definitions. For
purposes of the Plan, the following terms have the meanings set forth below: “Accrued Obligations” has the meaning for that
term in Section 5(a).

 

“Affiliate”
means any company or other entity controlled by, controlling or under common control with the Company.

 

“Base Monthly Salary”
means one-twelfth of the Participant’s annual rate of base salary in effect as of the Termination Date, disregarding any
reduction that would constitute Good Reason.

 

“Board” means
the Board of Directors of the Company

 

“Cause” means,
with respect to any Participant and as determined by the Committee:

 

(a) A violation
of such Participant’s obligations regarding confidentiality or the protection of sensitive, confidential or proprietary information,
or trade secrets;

 

(b) An act
or omission by such Participant resulting in such Participant being charged with a criminal offense which constitutes a felony or involves
moral turpitude or dishonesty;

 

(c) Conduct
by such Participant which constitutes poor performance, gross neglect, insubordination, willful misconduct or a breach of the Company’s
Code of Conduct or a fiduciary duty to the Company or its stockholders; or

 

(d) The Company’s
determination that such Participant violated state or federal laws relating to the workplace environment, including without limitation,
laws relating to sexual harassment or age, sex, race or other prohibited discrimination.

 

Any determination by
the Committee regarding whether an event constituting Cause shall have occurred shall be final, binding and conclusive.

 

“Change of Control”
means the occurrence of any of the following:

 

(a) A transaction
or a series of related transactions occurring after the Effective Date pursuant to which any Person or Group (other than the Company or
any Affiliate) becomes the Beneficial Owner of more than fifty percent (50%) of the total voting power of the Voting Stock of the Company,
on a Fully Diluted Basis;

 

(b) Individuals
who, as of the day following the IPO closing date for the first sale of Stock listed on a Stock Exchange or designated on a Securities
Market, constitute the Board (the “Incumbent Board”) (together with any new directors whose election by such Incumbent Board
or whose nomination by such Incumbent Board for election by the stockholders of the Company was approved by a vote of at least a majority
of the members of such Incumbent Board then in office who either were members of such Incumbent Board or whose election or nomination
for election was previously so approved) cease for any reason to constitute a majority of the members of such Board then in office;

 

     

     

    

 

(c) The Company
consolidates with, or merges with or into, any Person, or any Person consolidates with, or merges with or into, the Company (regardless
of whether the Company is the surviving Person), other than any such transaction in which the Prior Stockholders own directly or indirectly
at least a majority of the voting power of the Voting Stock of the surviving Person in such merger or consolidation immediately after
such transaction; or

 

(d) The consummation
of any direct or indirect sale, lease, transfer, conveyance, or other disposition (other than by way of reorganization, merger, or consolidation),
in one transaction or a series of related transactions, of all or substantially all of the assets of the Company and its Subsidiaries,
taken as a whole, to any Person or Group (other than the Company or any Affiliate), except any such transaction or series of transactions
in which the Prior Stockholders own directly or indirectly at least a majority of the voting power of the Voting Stock of such Person
or Group immediately after such transaction or series of transactions.

 

“Change of Control
Severance Multiple” means the applicable number of months for the Participant on Exhibit A.

 

“Code” means
the Internal Revenue Code of 1986, as amended.

 

“Committee”
means the Compensation Committee of the Board.

 

“Company”
means EPIEN Medical, Inc. and any successor to its business or assets, by operation of law or otherwise.

 

“Disability”
means the absence of the Participant from the Participant’s duties with the Company on a full-time basis for a period of time which
would entitle the Participant to receive benefits under the long-term disability policy in effect at the time of such illness or other
physical or mental incapacity.

 

“Effective Date”
means June 1, 2022.

 

“Employee”
means an employee of the Company or an Affiliate.

 

“ERISA” means
the Employee Retirement Income Security Act of 1974, as amended.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, as now in effect or as hereafter amended, and any successor thereto.

 

“Good Reason”
means

 

(a) A material
adverse change in the scope of the Participant’s responsibilities or authority, excluding any such change after a Change of Control
that is solely as a result of the Company’s common stock no longer being publicly traded on a national securities exchange;

 

(b) The material
reduction in the Participant’s annual base salary or target bonus percentage

 

(c) The reduction
in the aggregate in the Participant’s eligibility for participation in the Company’s benefit plans;

 

(d) The relocation
of the Participant’s principal place of work by more than 50 miles from its then current location; or

 

(e) The failure
of any successor to the Company in a Change of Control to expressly assume the Plan in writing within ten (10) days after the occurrence
of a Change of Control.

 

In order to terminate
employment for Good Reason, a Participant must, within 90 days of the initial existence of circumstances constituting Good Reason, notify
the Company in writing of the existence of such circumstances, and the Company shall then have 30 days to remedy the circumstances. If
the circumstances have not been fully remedied by the Company, the Participant shall have 60 days following the end of such 30-day period
to exercise the right to terminate for Good Reason. If the Participant does not timely do so, the right to terminate for Good Reason shall
lapse and be deemed waived, and the Participant shall not thereafter have the right to terminate for Good Reason unless further circumstances
occur which themselves give rise to a right to terminate for Good Reason.

 

    2

     

    

 

“Group” has
the meaning set forth in Sections 13(d) and 14(d)(2) of the Exchange Act.

 

“Participant”
means an Employee who is designated as a Participant under Section 4(a) hereof, until such time as the Employee’s participation
ceases in accordance with Section 4(b) hereof.

 

“Person”
has the meaning set forth in Sections 13(d) and 14(d)(2) of the Exchange Act.

 

“Prior Stockholders”
means the holders of Stock and any other equity securities that represented one hundred percent (100%) of the Voting Stock of the Company
immediately prior to a reorganization, merger, or consolidation involving the Company or any sale or other disposition of all or substantially
all of the assets of the Company and its Subsidiaries, taken as a whole (or other equity securities into which the Stock or such other
equity securities are converted as part of such reorganization, merger, or consolidation).

 

“Protection Period”
means the 12-month period beginning on the date of the Change of Control. Notwithstanding anything in the Plan to the contrary,
if (i) a Participant’s employment is terminated within three months prior to a Change of Control for reasons that would have
constituted a Qualifying Termination if they had occurred following a Change of Control, (ii) the Participant reasonably demonstrates
that such termination (or Good Reason event) was at the request of a third party who had indicated an intention or taken steps reasonably
calculated to effect a Change of Control and (iii) a Change of Control involving such third party (or a party competing with such
third party to effectuate a Change of Control) does occur, then for purposes of the Plan the date immediately prior to the date of such
termination of employment or event constituting Good Reason shall be treated as a Change of Control. For purposes of determining the timing
and amount of payments and benefits to Participant under Section 5(c), the date of the actual Change of Control shall be treated
as the Participant’s Termination Date.

 

“Qualifying Termination”
means a termination of the Participant’s employment by the Company without Cause or by the Participant with Good Reason.

 

“Release”
means the waiver and release of claims required of the Participant prior to receipt of certain payments under this Plan as described in
Section 7 hereof.

 

“Securities Market”
means an established securities market.

 

“Separation from
Service” means a Participant’s separation from service from the Company and its Affiliates within the meaning of Section 409A
of the Code.

 

“Severance Multiple”
means the applicable number of months for the Participant on Exhibit A.

 

“Stock” means
the common stock, par value $0.0001 per share, of the Company, or any security into which shares of Stock may be changed or for which
shares of Stock may be exchanged.

 

“Stock Exchange”
means the New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or another established
national or regional stock exchange.

 

“Subsidiary”
means any corporation (other than the Company) or non-corporate entity with respect to which the Company owns, directly or indirectly,
fifty percent (50%) or more of the total combined voting power of all classes of Voting Stock.

 

“Target Bonus”
means the amount of cash incentive the participant would receive for performance at “target” for the year in which the Qualifying
Termination occurs, disregarding any reduction that would constitute Good Reason.

 

    3

     

    

 

“Termination Date”
means the date on which a Participant has a Separation from Service.

 

“Tier 1 Participant”
means each of the Participants designated as such by the Committee.

 

“Tier 2 Participant”
means each of the Participants designated as such by the Committee.

 

“Voting Stock”
means, with respect to any Person, capital stock of any class or kind ordinarily having the power to vote for the election of directors,
managers, or other voting members of the governing body of such Person. Without limiting the generality of the foregoing, the Stock shall
be Voting Stock of the Company.

 

4. Participation.

 

(a) Designation
of Participants. The Participants in the Plan are the executive officers and other key employees of the Company and its Affiliates
who are designated as Participants by the Compensation Committee of the Board (as reflected on Schedule A) and who execute a “Consent
to Accept Plan Benefits” in the form attached as Schedule B confirming their status as a Participant, which status is not revoked
under Section 19.

 

(b) Cessation
of Participation. A Participant shall cease to be a Participant and shall have no rights hereunder, without further action, when the
Participant ceases to be an Employee (unless such Participant is then entitled to severance payments and benefits as provided in Section 5).
A Participant entitled to severance payments and benefits under Section 5 shall remain a Participant in this Plan until the full
amount of the severance payments and benefits under the Plan have been fully paid and provided to the Participant.

 

(c) No Employment
Rights. Nothing in the Plan will reduce or eliminate the right of the Company and its Affiliates to terminate a Participant’s
employment at any time for any reason.

 

5. Payments
and Benefits on Termination of Employment.

 

(a) For Cause,
Death or Disability or Termination without Good Reason. If (x) a Participant terminates employment with the Company and its Affiliates
without Good Reason, (y) the Company and its Affiliates terminate a Participant’s employment for Cause or by reason of the
Participant’s Disability, or (z) a Participant’s employment is terminated by reason of the Participant’s death,
then the Participant will not be entitled to any compensation or benefits under the Plan other than the sum of:

 

(i) the portion
of the Participant’s base salary earned through the Termination Date, to the extent not theretofore paid;

 

(ii) the
amount of any annual incentive compensation under the annual incentive plan applicable to the Participant that has been earned by the
Participant for a completed fiscal year preceding the Termination Date, but has not yet been paid to the Participant; and

 

(iii) any
accrued paid vacation, sick leave and other paid time-off to the extent not theretofore paid (the sum of the amounts described
in clauses (i), (ii) and (iii) are hereinafter referred to as the “Accrued Obligations”).

 

The Accrued Obligations will be paid to the
Participant in a lump sum within 20 calendar days after the Participant’s Termination Date or at any earlier legally required time.

 

(b) Qualifying
Termination Other Than During Protection Period. In the event of a Participant’s Qualifying Termination other than during the
Protection Period, the Participant will be entitled to receive the payments and benefits provided below:

 

(i) Accrued
Obligations. The Accrued Obligations, payable in a lump sum within 20 calendar days after the Participant’s Termination Date
or at any earlier legally required time,

 

(ii) Severance
Payments. Subject to Sections 6, 7 and 8, a lump sum severance payment equal to the Participant’s Base Monthly Salary for the
number of months equal to the Participant’s Severance Multiple plus the Participant’s Target Bonus times a fraction, the numerator
of which is the Participant’s Severance Multiple and the denominator of which is 12, payable within 20 calendar days after the Release
described in Section 7 becomes effective and irrevocable in accordance with its terms, but no later than 70 days after the Participant’s
Termination Date.

 

    4

     

    

 

(iii) Health
Care Coverage. At the Company’s option, the Participant and the Participant’s eligible dependents shall be entitled either
(A) to receive a lump sum amount equal to the current cost of continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation
Act (“COBRA”) under the Company’s medical and dental plans in which the Participant participated prior to the Participant’s
Termination Date for the number of months equal to the Participant’s Severance Multiple, payable within 20 calendar days after the
Release described in Section 7 becomes effective and irrevocable in accordance with its terms, but no later than 70 days after the
Participant’s Termination Date, or (B) to continue to participate in the Company’s medical and dental plans in which
the Participant participated immediately prior to the Participant’s Termination Date, in each case for the number of months equal
to the Participant’s Severance Multiple, commencing with the first calendar month following the Termination Date (the “Benefit
Continuation Period”); provided, however, that if the Company elects option (B) above, the Benefit Continuation Period shall
cease when the Participant becomes eligible for any such coverage under a plan maintained by another employer. The Participant’s
continued participation in the Company’s medical and dental plans shall be on terms not less favorable than those in effect for
active employees of the Company, subject to the Participant making the monthly premium payment of the amount required for such coverage
during the Benefit Continuation Period by active employees of the Company. The Benefit Continuation Period shall run concurrently with
(and shall count against) the Company’s obligation to provide continuation coverage pursuant to COBRA.

 

(c) Qualifying
Termination During Protection Period. In the event of a Participant’s Qualifying Termination during the Protection Period, the
Participant will be entitled to receive the payments and benefits provided below:

 

(i) Accrued
Obligations. The Accrued Obligations, payable in a lump sum within 20 calendar days after the Participant’s Termination Date
or at any earlier legally required time,

 

(ii) Change
of Control Severance Payment. Subject to Sections 6, 7 and 8, a lump sum severance payment in an amount equal to the Participant’s
Base Monthly Salary multiplied by the Participant’s Change of Control Severance Multiple plus the Participant’s Target Bonus
times a fraction, the numerator which is the Participant’s Change of Control Severance Multiple and the denominator of which is
12, payable within 20 calendar days after the Release described in Section 7 becomes effective and irrevocable in accordance with
its terms, but no later than 70 days after the Participant’s Termination Date. Such payment shall be reduced, if applicable, by
any severance payments made to the Participant under Section 5(b)(ii) prior to the Change of Control.

 

(iii) Change
of Control Health Care Coverage. At the Company’s option, the Participant and the Participant’s eligible dependents shall
be entitled either (A) to receive a lump sum amount equal to the current cost of continuation coverage pursuant to COBRA under the
Company’s medical and dental plans in which the Participant participated prior to the Participant’s Termination Date for the
number of months equal to the Participant’s Change of Control Severance Multiple, payable within 20 calendar days after the Release
described in Section 7 becomes effective and irrevocable in accordance with its terms, but no later than 70 days after the Participant’s
Termination Date, or (B) to continue to participate in the Company’s medical and dental plans in which the Participant participated
immediately prior to the Participant’s Termination Date, in each case for the number of months equal to the Participant’s
Change of Control Severance Multiple, commencing with the first calendar month following the Termination Date (the “Change of Control
Benefit Continuation Period”); provided, however, that if the Company elects option (B) above, the Change of Control Benefit
Continuation Period shall cease when the Participant becomes eligible for any such coverage under a plan maintained by another employer.
Such continued participation shall be reduced, if applicable, by the number of months of the Participant continued participation in the
Company’s medical and dental plans under Section 5(b)(iii) prior to the Change of Control. The Participant’s continued
participation in the Company’s medical and dental plans shall be on terms not less favorable than those in effect for active employees
of the Company, subject to the Participant making the monthly premium payment of the amount required for such coverage during the Change
of Control Benefit Continuation Period by active employees of the Company. The Change of Control Benefit Continuation Period shall run
concurrently with (and shall count against) the Company’s obligation to provide COBRA continuation coverage.

 

    5

     

    

 

6. Impact
of Section 4999 Excise Tax. The payments and benefits to Participants under the Plan shall be subject to reduction, if applicable,
in accordance with the provisions of Exhibit B.

 

7. Release. The
severance compensation and benefits to be provided under Sections 5(b)(ii), 5(b)(iii), 5(c)(ii), and 5 (c)(iii) shall be provided only
if the Participant timely executes and does not timely revoke a Release; provided that the Company has delivered, or has made a good faith
effort to deliver, a form of the Release to the Participant no later than the fifth business day after the Participant’s Termination
Date. The Release must be signed by the Participant (or his legal representative, if applicable) and become effective and irrevocable
in accordance with its terms (taking into account any applicable revocation period set forth therein) by the date specified by the Company,
which shall be no later than sixty-five days after the Participant’s Termination Date. If the Participant fails to execute and furnish
the Release, or if the Release furnished by the Participant has not become effective and irrevocable in accordance with its terms (taking
into account any applicable revocation period set forth therein) by the fiftieth day after the Participant’s Termination Date, the
Participant will not be entitled to any payment or benefit under the Plan other than the Accrued Obligations.

 

8. Covenants. The
severance compensation and benefits to be provided under Sections 5(b)(ii), 5(b)(iii), 5(c)(ii), and 5(c)(iii) are subject to the Participant’s
continued compliance with the covenants set forth on Exhibit C. The Company’s obligations and the Participant’s right, if
any, to severance compensation and benefits under Sections 5(b)(ii), 5(b)(iii), 5 (c)(ii), and 5(c)(iii) shall cease in the event of a
material breach by the Participant of any provision of Exhibit C (and, in only those cases where such material breach is curable, the
failure to cure such material breach within 10 business days after written notice to the Participant, which notice details, with reasonable
specificity, such material breach). Any such cessation of payment shall not reduce any monetary damages that may be available to the Company
as a result of such breach.

 

9. No
Mitigation. In no event shall the Participant be obligated to seek other employment or take any other action by way of mitigation
of the amounts payable to the Participant under any of the provisions of this Plan and such amounts shall not be reduced whether or not
the Participant obtains other employment.

 

10. Effect
on Other Plans, Agreements and Benefits. It is a condition for eligibility to receive benefits under this Plan that, during the
term of the Plan, each Participant waive any and all cash severance and health continuation benefits to which he or she might otherwise
have been entitled under any prior agreement or arrangement with the Company or an Affiliate or a policy of the Company or
an Affiliate should the Participant experience a termination of employment with the Company and all its Affiliates,
and this Plan supersedes and replaces in all respects any rights a Participant had to such benefits from the Company other than as set
forth herein. Except to the extent expressly set forth herein, any benefit or compensation to which a Participant is entitled under any
agreement between the Participant and the Company or any of its Affiliates or under any plan maintained by the Company or any of its Affiliates
in which the Participant participates or participated shall not be modified or lessened in any way as a consequence of the Participant’s
participation in this Plan, but shall be payable or provided according to the terms of the applicable plan or agreement.

 

11. Administration. Except
as otherwise specifically provided herein, the Committee shall administer the Plan and shall have full and final authority in its discretion
to take all actions determined by the Committee to be necessary in the administration of the Plan. The Committee may delegate, subject
to such terms as the Committee shall determine, any of its authority hereunder to such person or persons from time to time as it may designate.
In the event of such delegation, all references to the Committee in this Plan shall be deemed references to such delegates as it relates
to those aspects of the Plan that have been delegated.

 

12. Claims
for Benefits.

 

(a) Filing a
Claim. Any Participant who wishes to file a claim for benefits under the Plan shall file his or her claim in writing with the Committee.

 

    6

     

    

 

(b) Review of
a Claim. The Committee shall, within 90 days after receipt of such written claim (unless special circumstances require an extension
of time, but in no event more than 180 days after such receipt), send a written notification to the Participant as to its disposition.
If the claim is wholly or partially denied, such written notification shall (i) state the specific reason or reasons for the denial,
(ii) make specific reference to pertinent Plan provisions on which the denial is based, (iii) provide a description of any additional
material or information necessary for the Participant to perfect the claim and an explanation of why such material or information is necessary,
and (iv) set forth the procedure by which the Participant may appeal the denial of his or her claim, including, without limitation,
a statement of the claimant’s right to bring an action under Section 502(a) of ERISA following an adverse determination on
appeal.

 

(c) Appeal of
a Denied Claim. If a Participant wishes to appeal the denial of his or her claim, he or she must request a review of such denial by
making application in writing to the Committee within 60 days after receipt of such denial. Such Participant (or his or her duly authorized
legal representative) may, upon written request to the Committee, review any documents pertinent to his or her claim, and submit in writing,
issues and comments in support of his or her position. A Participant who fails to file an appeal within the 60-day period set
forth in this Section 9(c) shall be prohibited from doing so at a later date or from bringing an action under ERISA.

 

(d) Review of
a Claim on Appeal. Within 60 days after receipt of a written appeal (unless the Committee determines that special circumstances, such
as the need to hold a hearing, require an extension of time, but in no event more than 120 days after such receipt), the Committee shall
notify the Participant of the final decision. The final decision shall be in writing and shall include (i) specific reasons for the
decision, written in a manner calculated to be understood by the claimant, (ii) specific references to the pertinent Plan provisions
on which the decision is based, (iii) a statement that the claimant is entitled to receive, upon request and free of charge, reasonable
access to, and copies of, all documents relevant to the claim for benefits, and (iv) a statement describing the claimant’s
right to bring an action under Section 502 (a) of ERISA.

 

13. Participants
Acceptance of Plan. Each Participant shall indicate his or her acceptance and ratification of, and consent to, all of the terms
and conditions of the Plan and any action taken under the Plan by the Committee or the Company or its Affiliates, in any case in accordance
with the terms and conditions of the Plan, by executing a “Consent to Accept Plan Benefits” attached as Schedule B.

 

14. Successors.

 

(a) Company Successors.
This Plan shall bind any successor of the Company, its assets or its businesses (whether direct or indirect, by purchase, merger, consolidation
or otherwise), in the same manner and to the same extent that the Company would be obligated under this Plan if no succession had taken
place. In the case of a Change of Control or any transaction in which a successor would not by the foregoing provision or by operation
of law be bound by this Plan, the Company shall require such successor expressly and unconditionally to assume and agree to perform the
Company’s obligations under this Plan, in the same manner and to the same extent that the Company would be required to perform if
no such succession had taken place. The term “Company,” as used in this Plan, shall mean the Company as heretofore defined
and any successor or assignee to the business or assets which by reason hereof becomes bound by this Plan.

 

(b) Participant
Successors. This Plan shall inure to the benefit of and be enforceable by the Participant’s personal or legal representatives,
executors, administrators, successors, heirs, distributees and/or legatees. The rights under this Plan are personal in nature and neither
the Company nor any Participant shall, without the consent of the other, assign, transfer or delegate any rights or obligations hereunder
except as expressly provided in this Section. Without limiting the generality of the foregoing, the Participant’s right to receive
any benefits hereunder shall not be assignable, transferable or delegable, whether by pledge, creation of a security interest or otherwise,
other than by a transfer by his or her will or by the laws of descent and distribution and, in the event of any attempted assignment or
transfer contrary to this Section, the Company shall have no liability to pay any amount so attempted to be assigned, transferred or delegated.

 

    7

     

    

 

15. Resolutions
of Disputes.

 

(a) Arbitration.
Any and all controversies arising out of or relating to the validity, interpretation, enforceability, or performance of the Plan will
be solely and finally settled by means of binding arbitration in Minneapolis, Minnesota. The arbitration shall be conducted in accordance
with the applicable employment dispute resolution rules of the American Arbitration Association. The arbitration will be final, conclusive
and binding upon the parties. All arbitrator’s fees and related expenses shall be divided equally between the parties.

 

(b) Legal Fees.
The arbitrator shall award the Participant attorneys’ fees and expenses if the Participant prevails on at least one material issue
in dispute, including the attorneys’ fees and expenses the Participant incurs in connection with any appeal or the enforcement of
any award. Any award of attorneys’ fees and expenses to the Participant shall be paid by the Company within 60 days following the
award of such fees and costs by the arbitrator (or, if later, when such fees and expenses are incurred), but in no event later than December 31
of the calendar year following the year of the conclusion of the arbitration (or, if later, December 31 of the calendar year following
the year in which such fees and expenses are incurred).

 

16. Unfunded
Plan Status. All payments pursuant to the Plan shall be made from the general funds of the Company and no special or separate
fund shall be established or other segregation of assets made to assure payment. No Participant or other person shall have under any circumstances
any interest in any particular property or assets of the Company as a result of participating in the Plan.

 

17. Withholding. The
Company shall have the right to deduct and withhold from any amounts payable under the Plan such federal, state, local or other taxes
as are required to be withheld pursuant to any applicable law or regulation.

 

18. Notice. For
the purpose of this Plan, notices and all other communications provided for in this Plan shall be in writing and shall be deemed to have
been duly given when actually delivered or mailed by United States registered mail, return receipt requested, postage prepaid, addressed
to the Secretary at the Company’s corporate headquarters address, and to the Participant (at the last address of the Participant
on the Company’s books and records).

 

19. Amendment
and Termination. The Company may amend (in whole or in part) or terminate the Plan provided that (i) any amendment or termination
that reduces the benefits under Section 5(b) or any notice from the Committee revoking the Participant’s participation in the
Plan will not be effective prior to the date that is six months after the date the Company has provided written notice to each affected
Participant of such amendment or termination or revocation and (ii) no amendment or termination or revocation will be effective for
a period of twelve months after a Change of Control if a Change of Control occurs within six months after the date the Company has provided
written notice to each Participant of such amendment or termination or revocation. Notwithstanding the foregoing, no termination shall
reduce or terminate any Participant’s right to receive, or continue to receive, any payments and benefits that became payable in
respect of a termination of employment that occurred prior to the date of such termination of the Plan.

 

20. Governing
Law. Except to the extent preempted by federal law, the provisions of the Plan shall be governed and construed in accordance
with the laws of the State of Minnesota without regard to the conflict of law provisions thereof.

 

21. Validity
and Severability. The invalidity or unenforceability of any provision of the Plan shall not affect the validity or enforceability
of any other provision of the Plan, which shall remain in full force and effect, and any prohibition or unenforceability in any jurisdiction
shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

    8

     

    

 

22. Headings;
Interpretation. Headings in this Plan are inserted for convenience of reference only and are not to be considered in the construction
of the provisions hereof. Unless the context clearly requires otherwise, the masculine pronoun wherever used herein shall be construed
to include the feminine pronoun.

 

23. Section
409A.

 

(a) It is intended that
the payments and benefits provided under the Plan shall be exempt from the application of the requirements of Section 409A of the
Code. This Plan shall be construed, administered and governed in a manner that effects such intent, and the Committee shall not take any
action that would be inconsistent with such intent. Specifically, any taxable benefits or payments provided under this Plan are intended
to be separate payments that qualify for the “short-term deferral” exception to Section 409A of the Code to the maximum
extent possible, and to the extent they do not so qualify, are intended to qualify for the separation pay exceptions to Section 409A
of the Code, to the maximum extent possible. To the extent that none of these exceptions (or any other available exception) applies, then
notwithstanding anything contained herein to the contrary, and to the extent required to comply with Section 409A of the Code, if
a Participant is a “specified employee,” as determined under the Company’s policy for identifying specified employees
on his or her Termination Date, then all amounts due under this Plan that constitute a “nonqualified deferred compensation”
within the meaning of Section 409A of the Code, that are provided as a result of a Separation from Service within the meaning of
Section 409A of the Code, and that would otherwise be paid or provided during the first six months following the Termination Date,
shall be accumulated through and paid or provided on the first business day that is more than six months after the date of the Termination
Date (or, if the Participant dies during such six-month period, within 90 days after the Participant’s death). If the
payments and benefits provided under the Plan replace payments or benefits under a Participant’s other applicable arrangement that
constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code, payments under the Plan
shall be made on the schedule specified under the other arrangement to the extent necessary to avoid a violation of Section 409A
of the Code.

 

(b) With regard to any
provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A
of the Code: (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another
benefit; (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any calendar year
shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; and
(iii) such payments shall be made on or before the last day of the Participant’s calendar year following the calendar year
in which the expense occurred, or such earlier date as required hereunder.

 

(c) The payments and
benefits provided under this Plan may not be deferred, accelerated, extended, paid out or modified in a manner that would result in the
imposition of an additional tax under Section 409A of the Code upon Participants. The tax treatment of the benefits provided under
this Plan is not warranted or guaranteed. Neither the Company, its Affiliates nor their respective directors, officers, employees or advisers
shall be held liable for any taxes, interest, penalties or other monetary amounts owed by a Participant (or any other individual claiming
a benefit through the Participant) as a result of this Plan.

 

    9

     

    

 

EXHIBIT A 

SEVERANCE MULTIPLE
AND CHANGE OF CONTROL SEVERANCE MULTIPLE

 

	Severance Multiple	 
	Tier 1 Participants	24
	Tier 2 Participants	12
	Change of Control Severance Multiple	 
	Tier 1 Participants	24
	Tier 2 Participants	18

 

    10

     

    

 

EXHIBIT B 

EFFECT OF SECTION
4999 EXCISE TAX

 

(a) Anything in this
Plan to the contrary notwithstanding, in the event it shall be determined that any Payment (as hereinafter defined) would be subject to
the Excise Tax (as hereinafter defined), the right to receive any Payment under this Plan shall be reduced if but only if:

 

(i) such right to such Payment,
taking into account all other Payments to or for Participant, would cause any Payment to the Participant under this Plan to be considered
a “parachute payment” within the meaning of Section 280G(b)(2) of the Code as then in effect; and

 

(ii) as a result of receiving
a parachute payment and paying any applicable tax (including Excise Tax) thereon, the aggregate after-tax amounts received by
the Participant under this Plan and all Payments would be less than the maximum after-tax amount that could be received by Participant
without causing any such Payment to be considered a parachute payment.

 

In the event that the
receipt of any such right to Payment under this Plan, in conjunction with all other Payments, would cause the Participant to be considered
to have received a parachute payment under this Plan that would have the effect of decreasing the after-tax amount received
by the Participant as described in clause (ii) of the preceding sentence, then the amounts payable under this Plan shall be reduced
so that the Parachute Value of all Payments, in the aggregate, equals the Safe Harbor Amount.

 

To the extent that the
payment of any compensation or benefits to a Participant is required to be reduced by this Exhibit B, such reduction shall be implemented
by determining the “Parachute Payment Ratio” (as hereinafter defined) for each parachute payment and then reducing the parachute
payments in order beginning with the parachute payment with the highest Parachute Payment Ratio. For parachute payments with the same
Parachute Payment Ration, such parachute payments shall be reduced based on the time of payment of such parachute payments, with amounts
having later payment dates being reduced first. For parachute payments with the same Parachute Payment Ratio and the same time of payment,
such parachute payments shall be reduced on a pro rata basis (but not below zero) prior to reducing parachute payments with a lower Parachute
Payment Ratio.

 

(b) Definitions.
The following terms shall have the following meanings for purposes of this Exhibit B.

 

(i) “Excise Tax”
shall mean the excise tax imposed by Section 4999 of the Code, together with any interest or penalties imposed with respect to such
excise tax.

 

(ii) “Parachute Payment
Ratio” shall mean a fraction the numerator of which is the value of the applicable parachute payment for purposes of Section 280G
of the Code and the denominator of which is the intrinsic value of such parachute payment.

 

(iii) “Parachute Value”
of a Payment shall mean the present value as of the date of the Change of Control for purposes of Section 280G of the Code of the
portion of such Payment that constitutes a “parachute payment” under Section 280G(b)(2), as determined for purposes of
determining whether and to what extent the Excise Tax will apply to such Payment.

 

(iv) A “Payment”
shall mean any payment or distribution in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to or
for the benefit of the Participant, whether paid or payable pursuant to this Agreement or otherwise.

 

(v) The “Safe Harbor
Amount” means 2.99 times the Participant’s “base amount,” within the meaning of Section 280(b)(3) of
the Code.

 

    11

     

    

 

EXHIBIT C

COVENANTS

 

1. Confidential Information

 

(a) For purposes of this
Exhibit C “Confidential Information” means ideas, concepts, information and material that constitute trade secrets and/or
proprietary and confidential information of the Company and its Affiliates. Confidential Information includes, but is not limited to,
information and knowledge pertaining to products and services offered, ideas, plans, manufacturing, marketing, pricing, distribution and
sales methods and systems, sales and profit figures, customer and client lists, and relationships between the Company or its subsidiaries
and their respective affiliates, dealers, distributors, wholesalers, customers, clients, suppliers and other who have business dealings
with the Company or any of its subsidiaries.

 

(b) Confidential Information
is the sole and exclusive property of the Company. The Participant must not, either during or after the term of this Agreement, directly
or indirectly disclose any Confidential Information to any third party without the written permission of the Board, except as required
by his employment with the Company, unless such information is in the public domain for reasons other than the Participant’s conduct,
or except as may be required by law (provided that the Participant shall give the Company notice of any disclosure required by law so
that the Company shall have a reasonable opportunity to attempt to preclude such disclosure). The Participant shall not use Confidential
Information to his own advantage or the advantage of parties other than the Company. The Participant shall take all steps necessary to
protect the confidentiality of all Confidential Information and to inform the Company immediately of any attempted or actual disclosure
of Confidential Information to any third party. The Participant agrees that, upon request of the Company or termination of employment,
whichever is first, he shall turn over to the Company all documents, memoranda, notes, plans, records or material in his possession or
control that contain or are derived from Confidential Information.

 

(c) If at any time the
Participant has any material information which belongs to any former employer that the Participant is not entitled to have or use for
the benefit of the Company and its Affiliates, the Participant shall promptly return any such materials to the Participant’s former
employer or obtain any necessary consents. The Participant is not permitted to use or refer to any such materials in the performance of
the Participant’s duties.

 

2. Non-Competition. During
the period of the Participant’s employment with the Company and its Affiliates and continuing for the number of months after the
Termination Date equal to the applicable of the Participant’s Change of Control Severance Multiple or Severance Multiple (the “Restricted
Period”), the Participant shall not directly or indirectly own any interest in, manage, control, participate in, be employed by,
consult with, render services for, or in any manner engage in any Competing Business within any geographical area in which the Company
or any of its controlled affiliates engage or have active plans at the Termination Date to engage in such businesses. The restriction
is without specific geographic limitation inasmuch as the Company and its Affiliates conduct business on a nationwide and international
basis, that its sales and marketing prospects are for continued expansion both nationally and internationally, that access to the Company’s
Confidential Information would provide any national or international competitor with an unfair competitive advantage, and that, therefore,
the restrictions set forth in this Section are reasonable and properly required for the adequate protection of the legitimate interests
of the Company. Nothing herein shall prohibit the Participant from owning beneficially not more than 2% of any class of outstanding equity
securities or other comparable interests of any issuer that is publicly traded, so long as the Participant has no active participation
in the business of such issuer. For purposes hereof, the term “Competing Business” means any business that is engaged in the
production or sale of products that compete with the products produced, distributed or sold by the Company or its controlled affiliates
(or are in the process of being actively developed by such entities) as of the Date of Termination. This restriction shall not prevent
the Participant from working for a subsidiary, division, venture or other business or functional service unit (collectively a “Unit”)
of a Competing Business so long as (i) such Unit is not itself a Competing Business, (ii) the Participant does not manage or
participate in business activities or projects of any Unit that is a Competing Business, and (iii) the Participant otherwise strictly
complies with the restrictive covenants contained in this Exhibit.

 

    12

     

    

 

3. Nonsolicitation.

 

(a) During the Restricted
Period the Participant must not, as an individual, employee, consultant, agent, owner, partner, director or stockholder, directly or indirectly
solicit, call on or accept any business from any Customer of the Company or its subsidiaries. The term “Customer” means all
persons, firms or corporations to whom the Company or its subsidiaries sold products at any time during the one year period immediately
preceding when the Participant’s employment with the Company ceased, notwithstanding that some or all of such persons, firms or
corporations may have been induced to give business to the Company or its subsidiaries by the Participant.

 

(b) During the Restricted
Period the Participant must not take any action to divert from the Company or its subsidiaries any opportunity in the scope of any present
or contemplated future business of the Company or its subsidiaries that arose while he was employed by the Company.

 

(c) During the Restricted
Period the Participant must not directly or indirectly solicit, hire, employ or engage any employee or any former employee of the Company
or its Affiliates whose employment with the Company or its Affiliates ceased less than one year before the date of such solicitation,
enticement, hiring or engagement.

 

4. Non-Disparagement. Participant
at all times, both during and after Participant’s employment with the Company, shall not make any statement disparaging the Company,
any officer, director, employee or other service provider for the Company, or any product or service offered by the Company.

 

5. Scope of Restrictions. In
the event any provision relating to the time period or scope of the restrictions in this Exhibit C shall be declared by a court of competent
jurisdiction to exceed the maximum time period or scope such court deems reasonable and enforceable, such time period or scope shall be
deemed amended and reformed to the minimum degree necessary to be enforceable.

 

    13

     

    

 

SCHEDULE B

 

Consent to Accept Plan
Benefits

 

I agree and consent to
the terms of the EPIEN Medical, Inc. (“EPIEN”) Executive Severance and Change of Control Plan (the “Plan”). Further,
and for the avoidance of doubt, I acknowledge and agree that by signing below, I am waiving any and all existing rights to cash severance
or health continuation benefits to be provided to me by EPIEN in connection with a termination of employment from EPIEN, any successor
thereto or any Affiliate of either that employs me (collectively, the “Company”), that occurs during the term of the Plan
that I may otherwise be entitled to pursuant to any agreement, plan or arrangement (formal or informal, oral or written) with the Company.

 

	 	 
	 	Signature of [NAME] 
	 	 	 
	 	By:	         
	 	Title:	 
	 	Dated:	 

 

 

14Exhibit 10.16

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

RESEARCH
AGREEMENT

Amendment
No. 1

(Non-Clinical)

 

This
Amendment (“Amendment”) entered into this 25th day of January, 2022 (“Amendment Effective Date”), by and between
the University of Miami, (“University”) and Epien Medical (“Company”) amends the agreement between the parties dated
August 20, 2021 (“Agreement”) which is incorporated by referenced herein and made part of this Amendment.

 

Whereas,
University and Company entered into the Agreement for the a study entitled: Determination of the Debridement Effects of Revity on Deep
Dermal Wounds in a Porcine Model (“Study”).

 

Whereas,
University and Company intend to amend the Agreement as follows:

 

1. The
amount of funding for the conduct of the Study is being increased by $15,541.00. The total amount of funding is hereby amended to a total
of $38,902.00.

 

2. Except
as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall apply and remain in full force
and effect. All terms used herein shall have the same meaning as ascribed to them in the Agreement. To the extent any term or provision
of this Amendment conflicts with any term or provision of the Agreement, the terms and provisions of this Amendment shall prevail.

 

[Remainder
of page left intentionally blank]

 

     

     

    

 

IN
WITNESS THEREOF, the parties have executed this Amendment by their duly authorized officers or representatives:

 

	UNIVERSITY OF MIAMI:	 	 
	 	 
	/s/ D.
    Stewart MacIntyre III, JD	 
	Authorized University Representative	 
	D. Stewart MacIntyre III, JD	 
	Director, Office of Research Administration	 
	Name and Title	 
	 	 
	Feb 22, 2022	 
	Date	 

 

	Read
    and Understood:	 	 
	 	 	 
	PRINCIPAL
    INVESTIGATOR	 	 
	 	 	 
	/s/
    Stephen C. Davis	 	2/4/2022
	Stephen
    C. Davis	 	Date
	Research
    Professor	 	 
	University
    of Miami Miller School of Medicine	 	 
	Department
    of Dermatology & Cutaneous Surgery

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]